An AstraZeneca heart disease trial failure has put Alnylam under pressure. It's mounting a defense of its medicines.

Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. Eli Lilly said Tuesday it would buy ...

Daniel covers the intersection of the health industry and the federal government. He reports on corporate influence in government, the health consequences of federal policies, and the politics of ...

News on rare diseases, including the development of new treatments, the challenges of diagnosis and treatment and the stories of patients and their families. The page features in-depth reporting on ...

A newly acquired Novartis drug cut signs of inflammation. The test will be whether that can improve people's heart health.

RFK Jr.'s vaccine questions in Samoa, former Stanford president rebuts fraud allegations, and more health news from Morning ...

Opposition to abortion restrictions should focus on values, not statistics, writes David N. Hackney, author of “Impossible ...

A scramble to prepare for massive federal cuts across the health care system is hitting rural states like Maine particularly ...

Roivant's autoimmune drug approval, Cytokinetics reports full data for heart condition treatment, and more biotech news ...

A personalized cancer vaccine developed by Moderna and Merck may be a triumph of immunology and cancer biology. It might also be the triumph of an algorithm.

AstraZeneca detailed the surprise failure of a closely watched heart disease trial, a study with ripple effects for a ...

Juul has received FDA clearance to sell an updated version of its e-cigarette, which includes an optional age-verification ...